Halozyme Therapeutics (HALO) EBIT Margin Growth (5y) (2015 - 2026)
Halozyme Therapeutics (HALO) EBIT Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -801.00 |
| Dec 31, 2025 | -8,434.00 |
| Sep 30, 2025 | -18.00 |
| Jun 30, 2025 | 863.00 |
| Mar 31, 2025 | 6,615.00 |
| Dec 31, 2024 | 11,864.00 |
| Sep 30, 2024 | 10,933.00 |
| Jun 30, 2024 | 8,638.00 |
| Mar 31, 2024 | 4,357.00 |
| Dec 31, 2023 | 4,404.00 |
| Sep 30, 2023 | 14,054.00 |
| Jun 30, 2023 | 9,976.00 |
| Mar 31, 2023 | 10,999.00 |
| Dec 31, 2022 | -2,538.00 |
| Sep 30, 2022 | 2,718.00 |
| Jun 30, 2022 | 9,784.00 |
| Mar 31, 2022 | 15,762.00 |
| Dec 31, 2021 | 11,330.00 |
| Sep 30, 2021 | 13,666.00 |
| Jun 30, 2021 | 13,335.00 |